Caterpillar (CAT - Free Report) is a Zacks Rank #5 (Strong Sell) that is the largest global manufacturer of construction and mining equipment. The company, which is known for its iconic yellow machines, has struggled during the lockdowns. However, the stock has rallied 50% off the March panic lows.
While economies are reopening and the stock deserved a bounce, investors might want to think twice about further upside.
The Panic and Rally
The stock was crushed in early March, falling from $140 all the way to $87.50. After a very volatile April, the stock bottomed on a second test of $100 and has since pushed all the way back to $140.
Investors seem to think that CAT will not be phased by the economic damage that the shutdowns created. However, looking at earnings and estimates, the bulls might be getting ahead of themselves.
Earnings and Estimates
Caterpillar reported earnings in late April, seeing a 9% surprise on EPS to the downside. The company also missed on revenue and commented that Q2 will be worse than Q1 in relation to the virus.
The stocks recent up move has no fundamental basis as estimates continue to look horrendous. Over the last 60 days, next quarters estimates have fallen 24%, from $1.72 to $1.31. For next year, estimates have fallen 20% over the same time frame.
With numbers falling and remaining lower, investors should question if the stock deserves to be back at February levels. If the economy doesn’t bounce back like the market expects, CAT could see another volatile fall back into support levels.
Caterpillar has seen a volatile year, but is still at pre-pandemic levels for now. The stock is above all moving averages and as long as it can remain over the 200 day at $130, it could hold momentum. If that area breaks, we could see significant down side as sellers come in for fundamental reasons.
We have seen big moves higher in stocks like CAT on the back of the Fed. The question going forward is can the fundamentals fix themselves in the short-run or is there more severe damage that will harm the stock.
Breakout Biotech Stocks with Triple-Digit Profit Potential
The biotech sector is projected to surge beyond $775 billion by 2024 as scientists develop treatments for thousands of diseases. They’re also finding ways to edit the human genome to literally erase our vulnerability to these diseases.
Zacks has just released Century of Biology: 7 Biotech Stocks to Buy Right Now to help investors profit from 7 stocks poised for outperformance. Our recent biotech recommendations have produced gains of +50%, +83% and +164% in as little as 2 months. The stocks in this report could perform even better.
See these 7 breakthrough stocks now>>